Crimean-Congo hemorrhagic fever (CCHF) is a severe viral disease with high fatality rate.
Introduction
Crimean-Congo hemorrhagic fever (CCHF) is a severe viral disease with an average case fatality rate of 5-30%. CCHF virus is the most widespread tick-borne virus in the world, with cases reported from Africa, Middle East, Asia, Russia and southeastern Europe. The virus is transmitted to humans mainly by infected ticks from the genus Hyalomma or by contact with blood or tissues from infected humans and animals. CCHF virus is classified as a BSL-4 agent due to its high pathogenicity, possibility of spread from human to human and because there is no effective treatment or vaccine available [1] . Rapid diagnostics are essential for effective infection control and prevention of spread of the disease from human to human. Namely, healthcare professionals are at high risk of infection due to their close contact with patients especially during invasive and aerosolforming interventions and many nosocomial transmissions have been reported 1 .
Quick diagnostics provide the basis for the implementation of proper infection control measures and patient management [2] [3] [4] . Currently the diagnostics of acute CCHF relies mainly on the detection of viral RNA with Real-Time RT-PCR. This method enables quick, sensitive and specific detection, but is not suitable for point of care (POC) diagnostics, as it requires trained personnel and expensive equipment 5, 6 . Besides, these criteria are mostly not met in rural areas where CCHF is endemic 7 . Diagnostics of acute CCHF is also performed with ELISA for detection of IgG and IgM antibodies as well as CCHF virus nucleoprotein (NP) and rarely by virus isolation. Current serological assays provide reliable results and offer adequate sensitivity in clinical settings, however they all require trained personnel, are time consuming and not appropriate for POC diagnostics 7 . An ideal POC test for detection of CCHF IgG would have to exhibit sensitivity and specificity similar to or greater than the current sensitivity and specificity of standard inhouse and commercial ELISA tests that ranges between 66.9-90.2% and 95.8-100.0% respectively 5 . Besides it would ideally give quantitative results, be easy to use, robust and offer maximum operational safety to the user.
There is a need for point-of-care diagnostic assays allowing for quick and reliable, antibodies, nucleic acids) at the endface and the tip of an optical fiber. Target molecules then bind to the capture biomolecules and these can also bind to complementary labeled detection biomolecules. After exposure to a substrate, the marker enzyme oxidizes it and a chemiluminescent glow is produced as a side reaction that is collected 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 by the optical fiber and transduced to the detector 8 . Previously we developed fiberoptic biosensors for sensitive detection of antibodies against Ebola virus, Rift Valley Fever virus, Dengue virus, West-Nile and Hepatitis C [9] [10] [11] [12] [13] . The aim of this study is to develop a fiber-optic biosensor for accurate detection of antibodies against CCHF virus NP and to optimize the fiber-optic immobilization procedures so as to enhance overall signal.
Materials and methods

Materials
Methyl alcohol (136805) was purchased by Bio-Lab (Israel), acetic acid (45731, 99.8%
(v/v)) was purchased from Fluka, sulfuric acid (76649390, 95% (v/v)), hydrochloric acid 
CCHFV-N protein expression and purification
For expression 1-50ng of plasmid CCHFNhispET19# (provided by Ali Mirazimi) containing the nucleocapsid gene of CCHFV strain Ibr10200 was transformed into BL21 and plated out for overnight culture on LB amp plates at 37°C. Clones were picked and subsequently cultured overnight in 5ml LB amp at 37°C, 50ml LB amp culture for 24h at 28°C after transfer of 1 ml, and 500ml LB amp culture after transfer of 10 ml at 28°C during the following day until an OD260nm between 0.4-0.6 was reached (NanoDrop).
Expression was induced with 1 mM IPTG and the culture continued at 28°C overnight. A bacterial pellet was harvested by centrifugation at 4000g / 20min, washed with PBS, at 4°C on a shaker. After one additional centrifugation step the agarose was resuspended in 1ml buffer A1 and transferred into an empty column (Biorad, Germany).
The column was then successively washed with 20ml buffer B, 10ml buffer E1, and the 
Optical fiber immobilization
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Optic fibers were prepared according to the reference protocol described by Liebes et al. 14 
Fiber-optic chemiluminescent and Colorimetric immunoassay
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Protocol optimization
The initial immobilization protocol (Protocol 1) 14 was optimized in order to achieve maximum output chemiluminescence signal levels. For protocol optimization we immobilized 200 U/ml HRP on the fiber optic. Optimization steps are shown in Table 1 .
Steps with the highest chemiluminescence output comprise the optimized protocol (Protocol 2), which we used for the optic-fibre immobilization with CCHF virus NP.
We also evaluated the effect of two different HRP substrate compositions. We compared the output levels of the Immuno-star-HRPTM substrate (Bio-Rad), that includes 1:1 luminol/enhancer and stable peroxide buffer, and a substrate described by Vdovdenko et al. 15 that is based on the addition of two enhancers: SPTZ (sodium salt of 3-(10′-phenothiazinyl)propane-1-sulfonate) and MORP (4-morpholinopyridine). A total of 240µl substrate was added to each well.
Fiber-optic immunoassay for detection of CCHF antibodies
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Results and Discussion
The aim of this study was to develop and optimize a fiber optic biosensor for detection of CCHF virus antibodies. As a starting point we used a previously described immobilization protocol (Protocol 1) 14 and optimized each step in order to maximize the chemiluminescence output.
In the cleaning step we tested the effects of sonication and duration of methanol washing. We showed that sonication significantly increased the biosensor end point signal output (RLU 6857 vs. 1114 without sonication) and that methanol washing for 20 min was the most effective. Next we wanted to assess the efficacy of optical fiber activation (production of surface hydroxyl groups) using different activating solutions. Namely, we wanted to replace the piranha solution with a safer alternative as it is highly toxic and dangerous, requires special handling and disposal measures. However, our results show that the piranha solution was by far the most effective activator, with the biosensor output of 16669 RLU. Neither HCL, H 2 SO 4 , CH 3 COOH or H 3 PO 4 had comparable results (RLU: 3598, 9625, 1991, 5681, respectively).
Piranha solution was therefore used in the optimized protocol (Protocol 2). Next step was the optimization of the silanization process. We tested 3 different temperatures (30°C, 60°C and 90°C) and 3 different durations (30 min, 60 min, 90 min) of silanization.
We obtained the highest biosensor output at 60°C for 60 min (8660 RLU). In the last step we optimized the temperature and duration of treatment with sodium m-peroxidate.
The highest biosensor output was achieved at 25°C for 90 min (20594 RLU). The results of the protocol optimization are shown in Table 1 .
Next, we compared protocols 1 and 2 for their overall performance in the immunoassay, and as seen in Figure 1 , the sensitivity of protocol 2 is 100-fold higher (limit of detection for protocol 1 is antibody dilution 10 -4 and for protocol 2 is 10 -6 ) . The results show that optimization steps had great influence on the overall efficacy of the immunoassay.
Protocol 2 was therefore used for validation of the fiber-optic biosensor using patient sera. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 We also compared two different substrate formulations with respect to the overall biosensor output. We wanted to assess if enhancers (SPTZ or MORP) added to the luminol/peroxide substrate, would enhance the biosensor's output, and indeed, as seen in figure 2 , the addition of the two enhancers did increase the biosensor's output by roughly 10-fold. An additional advantage in using SPTZ/MORP enhancers is that they provide a more durable light signal that increases the biosensor's sensitivity 16 .
In the last step we evaluated the sensitivity of the developed fiber-optic biosensor for the detection of CCHF IgG antibodies in human sera. We tested the assay with both patients' sera. Fiber-optic biosensor detection was more sensitive than ELISAs. The lowest limit of detection of Patient 1 serum was 10-fold greater compared to ELISA, down to titer 1:1,000,000. The assay was also able to detect the low positive serum sample of Patient 2 down to titer 1:5,000 (Table 2 ).
Our results show that our fiber-optic biosensor is a suitable alternative for ELISA, for the detection of CCHF virus IgG antibodies. The assay enables rapid and sensitive detection of CCHF antibodies and can be manufactured as a semi-disposable, point-of-care device.
The technology also enables us to modify the device to enable detection of other biomolecules (e.g. CCHF RNA). Another advantage of the proposed biosensor is that it does not require trained personnel or expensive equipment for its operation. Today's diagnostic assays lack these features and are therefore available only at select diagnostic centers. However, the endemic areas of CCHF are mainly rural areas with limited access to these high-end diagnostic services. High pathogenicity of CCHF and the risk of human-to-human transmissions, especially in hospital settings, warrant the development of point-of-care devices that would enable quick, safe and reliable diagnostics of CCHF. The main advantage of the fiber optic biosensor is that it provides sensitive results and can be designed as a point-of-care device at a cost comparable to current standard ELISA assays. The assay could serve as a rapid, primary diagnostic tool for bedside CCHF diagnostics in endemic areas where extensive diagnostic equipment and trained personnel are not available. The fiber-optic biosensor could provide the necessary solution, however further studies are needed to determine the actual clinical sensitivity and specificity of the assay on a larger scale.
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